for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Geron Corporation

GERN.OQ

Latest Trade

1.43USD

Change

-0.01(-0.69%)

Volume

751,920

Today's Range

1.38

 - 

1.47

52 Week Range

0.96

 - 

6.66

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.44
Open
1.43
Volume
751,920
3M AVG Volume
33.78
Today's High
1.47
Today's Low
1.38
52 Week High
6.66
52 Week Low
0.96
Shares Out (MIL)
188.42
Market Cap (MIL)
271.33
Forward P/E
-3.36
Dividend (Yield %)
--

Next Event

Geron Corp at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Geron Reports Q2 Loss Per Share Of $0.08

Geron Provides Imetelstat Program Update

Geron Corp Reports Q1 Loss Per Share $0.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Industry

Biotechnology & Drugs

Contact Info

149 Commonwealth Dr Ste 2070

+1.650.4737700

http://www.geron.com

Executive Leadership

John A. Scarlett

Chairman of the Board, President, Chief Executive Officer

Olivia K. Bloom

Chief Financial Officer, Executive Vice President - Finance, Treasurer

Andrew J. Grethlein

Principal Operating Officer, Executive Vice President

Stephen N. Rosenfield

Executive Vice President, Corporate Secretary, Chief Legal Officer

Melissa A. Kelly Behrs

Executive Vice President, Chief Business Officer

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.190

2017

-0.180

2018

-0.150

2019(E)

-0.428
Price To Earnings (TTM)
--
Price To Sales (TTM)
388.72
Price To Book (MRQ)
1.73
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.18
Return on Equity (TTM)
-21.29

Latest News

BRIEF-Geron Corporation Reports Q4 Loss Per Share $0.05

* ORATION REPORTS FOURTH QUARTER AND ANNUAL 2017 FINANCIAL RESULTS AND RECENT EVENTS

BRIEF-Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019

* GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING Source text (http://bit.ly/2COKF0K) Further company coverage:

BRIEF-Geron Corp Q3 loss per share $0.04

* Geron Corporation reports third quarter 2017 financial results

BRIEF-Geron announces fast track designation grant for imetelstat

* Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes

BRIEF-Geron Q2 loss per share $0.04

* Geron Corporation reports second quarter 2017 financial results

BRIEF-Geron provides updates to imetelstat clinical development

* Expects imbark protocol-specified primary analysis to begin no later than q3 of 2018 Source text for Eikon: Further company coverage:

BRIEF-Geron Q1 loss per share $0.05

* Geron Corporation reports first quarter 2017 financial results and recent events

BRIEF-Geron Corp and Janssen Research & Development LLC has completed second internal data reviews of Imerge and Imbark

* Geron Corp - Janssen Research & Development, LLC has completed second internal data reviews of Imerge and Imbark

BRIEF-Geron qtrly loss per share $0.05

* Geron Corporation reports fourth quarter and annual 2016 financial results

BRIEF-Geron Corp reports loss per share of $0.02

* Geron Corporation reports third quarter 2016 financial results and recent events

BRIEF-Geron Corp and Janssen Pharmaceuticals enter into a license agreement

* On September 15, 2016, co, Janssen Pharmaceuticals Inc entered into a license agreement - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up